Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMMA Study for Relapsed Germ Cell Tumours
NCT01782339Phase 2Completed
- Sponsor
- Barts Health NHS Trust
- Start
- May 2012
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and oxaliplatin in germ cell tumor (GCT), sponsored by Barts Health NHS Trust. Primary endpoint: Objective Response Rate at 2 years. Started May 2012; status: completed.
02
Drugs
paclitaxeloxaliplatin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01782339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782339.